BRUSSELS, BELGIUM, April 26, 2023 (GLOBE NEWSWIRE) --
Mycoplasmas are the smallest known free-living microorganisms and are frequent contaminants of mammalian cell cultures. For the safety and purity of vaccines and other biological cell-derived products, it is important that the cell substrates and unprocessed bulk materials are free of adventitious agents, including mycoplasma. In many instances, mycoplasmas differ from other forms of bacteria, making them difficult to culture and identify. Testing is done to detect mycoplasma like Mycoplasma hominis, Mycoplasma genitalium, Mycoplasma pneumoniae, and Ureaplasma urealyticum which can cause nongonococcal urethritis (NGU), prostate inflammation (prostatitis), vaginal discharge, and pelvic inflammatory disease (PID) in both men and women.
An Increasing Concerns of Cell Culture Contamination to Propel the Demand of Mycoplasma Testing Market
Mycoplasmas frequently contaminate the fluids used in bioprocessing and cell culture. It is generally known that primary cell cultures have a minimum contamination rate of 1% and continuous cell cultures have a contamination rate of between 15% and 35% due to mycoplasma. Inefficient culturing techniques or malfunctioning laboratory apparatus can both result in mycoplasma contamination. Reusing pipet tips is an example of poor culture technique that might spread the contaminant by transferring mycoplasma-infected media into otherwise sterile media. Further, a faulty laminar flow might spread mycoplasma-carrying dust and aerosols throughout a biosafety cabinet, contaminating all the medium and cells within.
The mycoplasmas enter the cell culture through various difficulties to trace sources. These include workers in the lab, serum, material used in cell culture, water baths, incubators, etc. Among the aforementioned sources, contamination by humans’ accounts for the largest share. The contaminants can be transmitted through dirty clothing, lab gear, human speaking close to a laminar airflow, the scalp, sneezing, coughing, etc. Also, wherever the cell cultures are kept, a steady inflow of people will raise the possibility of contamination. Out of over 190 total species of mycoplasma, only 20 distinct mycoplasma species of human, bovine, and porcine origin have been found in cell culture. Eight of the species account for almost 95% of all mycoplasma contamination in cell culture. These include M. arginini (bovine), M. fermentans (human), M. hominis (human), M. hyorhinis (porcine), M. orale (human), M. pirum (human), M. salivarium (human), and Acholeplasma laidlawii (bovine).
Routine testing is the best protection against mycoplasma contamination that can quickly identify contaminated cultures and reagents. In the case of batch adulteration or a product recall, contamination of cell substrates used in the development of biopharmaceuticals constitutes a serious economic risk for manufacturers as well as a potential safety concern for patients. Regular mycoplasma testing is needed to be performed during the product manufacturing and development phase to reduce these risks.
Key Strategies Adopted by the Leading Market Players and Laboratories in Mycoplasma Testing Market
Continuous advancements and developments in mycoplasma detection have enabled market players to develop innovative, rapid, and easy-to-use tests. Such advancements tend to provide a competitive edge to all manufacturers and hence, all leading players are focusing on increasing investments for new product development and expanding their geographic reach to strengthen their position in this high growth mycoplasma testing market.
Some of the recent developments are listed as below-
- In February 2023, SwiftDx announced the launch of its mycoplasma detection kit. The SwiftDx Mycoplasma Detection Kit is a new lateral flow test for the detection of mycoplasma contamination offering a faster and more convenient solution.
- In April 2022, AlphaBiolabs launched sexually-transmitted infection (STI) testing to detect chlamydia, gonorrhoea, mycoplasma genitalium, mycoplasma hominis, trichomoniasis, ureaplasma parvum (UTI), and ureaplasma urealyticum (UTI).
- In December 2021, Asahi Kasei Medical Co., Ltd. completely acquired Bionique Testing Laboratories LLC, one of the providers of mycoplasma testing services for the biotherapeutics and life-sciences industries in the US.
Irrespective of the upcoming challenges in mycoplasma testing market such as lengthy turnaround time, quality control concerns, long analytical and lead time, among others, the global mycoplasma testing market has a vast potential to grow at a significant rate and is projected to gain a consistent momentum in the upcoming years due to a strong emphasis on innovation, greater acceptance in biopharmaceutical manufacturers across the world, and development of rapid mycoplasma testing by top market players operating in mycoplasma testing market, among others.
For instance, assays based on nucleic-acid amplification techniques (NAT), such as polymerase chain reaction (PCR), have potential to address the challenges associated with mycoplasma testing such as turnaround time and quality control.
Competitive Landscape Analysis: Mycoplasma Testing Market
The global mycoplasma testing market is marked by the presence of well-established market players such as Thermo Fisher Scientific, Inc. (US); Charles River Laboratories International, Inc. (US); Merck KGaA (Germany); Lonza Group (Switzerland); PromoCell GmbH (Germany); American Type Culture Collection (US); and others.
Explore Detailed Insights on Mycoplasma Testing Market Report @ https://meditechinsights.com/mycoplasma-testing-market/
About Medi-Tech Insights:
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.
Contact Us:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/
Attachment
